Treatment Decisions in Non-Small Cell Lung Cancer: Applying the Evidence to the Management of Advanced Disease

Lung cancer is the leading cause of cancer death in the United States. The most common form of this tumor is non-small cell lung cancer (NSCLC), which accounts for the vast majority of cases and is often diagnosed at advanced stages. Although clinical needs in the management of advanced disease clearly remain, the emergence of novel approaches to treat NSCLC has improved outcomes in recent years. It is important for clinicians to understand the emerging and evolving role of molecular and histologic markers in NSCLC care. As with any cancer, effective patient-provider communication and patient involvement in treatment decisions are also integral to the management of patients with these tumors.

This case-based program will examine a number of important topics relevant to the contemporary management of advanced NSCLC. A major area of focus will be the role of histology and molecular markers in the clinical decision-making process. Individual patient factors that impact treatment decisions will also be addressed.

Available until August 9, 2011.
Physicians: 1.0 AMA PRA Category 1 Credit^™
Nurses: 1.0 contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)

This activity is jointly sponsored by SCEPTER™ and Quintiles Medical Education. This activity is co-provided by Global Education Group and SCEPTER™.